Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-02-05
DOI
10.3389/fonc.2018.00016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRCA mutations in the manifestation and treatment of ovarian cancer
- (2017) Zimin Pan et al. Oncotarget
- PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
- (2016) G E Konecny et al. BRITISH JOURNAL OF CANCER
- A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis
- (2016) Yali Han et al. DISEASE MARKERS
- Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
- (2016) Aniello Cerrato et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets
- (2016) Si Sun et al. Oncotarget
- Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
- (2016) Katherine Karakasis et al. Frontiers in Oncology
- Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
- (2015) Xi-Chun Hu et al. LANCET ONCOLOGY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries
- (2015) Janusz Menkiszak et al. Ginekologia Polska
- Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
- (2014) Barbara Lupo et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
- (2014) T. Byrski et al. BREAST CANCER RESEARCH AND TREATMENT
- Recurrent mutations of BRCA1 and BRCA2 in Poland: an update
- (2014) M. Szwiec et al. CLINICAL GENETICS
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- A Comprehensive Focus on Global Spectrum ofBRCA1andBRCA2Mutations in Breast Cancer
- (2013) Fatemeh Karami et al. Biomed Research International
- Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
- (2013) Angela Vasaturo et al. Frontiers in Immunology
- Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
- (2012) J. DeLigio et al. Anti-Cancer Agents in Medicinal Chemistry
- Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management
- (2012) Simone Heidemann et al. BREAST CANCER RESEARCH AND TREATMENT
- Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
- (2012) Ali I. Shamseddine et al. CHEMOTHERAPY
- STRUCTURE-FUNCTION OF THE TUMOR SUPPRESSOR BRCA1
- (2012) Serena L. Clark et al. Computational and Structural Biotechnology Journal
- BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
- (2011) Rinske Drost et al. CANCER CELL
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population
- (2010) O. Lavie et al. ANNALS OF ONCOLOGY
- Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo
- (2010) Pierfrancesco Tassone et al. CANCER BIOLOGY & THERAPY
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer
- (2009) K. Rhiem et al. CLINICAL ONCOLOGY
- Structural basis for recruitment of BRCA2 by PALB2
- (2009) Antony W Oliver et al. EMBO REPORTS
- BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells
- (2009) Joshua D. O'Donnell et al. GYNECOLOGIC ONCOLOGY
- PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
- (2009) F. Zhang et al. MOLECULAR CANCER RESEARCH
- Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer
- (2009) Fleur Huang et al. Nature Reviews Clinical Oncology
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
- (2008) E. M. Swisher et al. CANCER RESEARCH
- BRCA1-Associated Protein 1 Interferes with BRCA1/BARD1 RING Heterodimer Activity
- (2008) H. Nishikawa et al. CANCER RESEARCH
- Platinum Resistance: The Role of DNA Repair Pathways
- (2008) L. P. Martin et al. CLINICAL CANCER RESEARCH
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations
- (2008) David S.P. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started